Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Humans have been attempting to combat cancer since the time of the Ancient Egyptians, and recent decades have seen remarkable progress. However, tumor cells have developed sophisticated ways to evade ...

One of the best ways to defeat cancer is by rousing the immune system to attack it. Experts have thought that immune cells had to be inside of tumors for one type of immunotherapy, known as checkpoint ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

Immune checkpoint inhibitors (ICIs) emerged in the US about 15 years ago as an exciting class of cancer treatments that have achieved complete and durable remissions for thousands of people with ...

For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

WASHINGTON — Immune checkpoint inhibitor (ICI) therapy does not increase mortality in people with preexisting autoimmune diseases, new research has found. Results from a large database analysis of ...

Patients with cancer who receive immune checkpoint inhibitors (ICIs) have more than twice the risk for developing psoriasis compared with those who receive other treatments. Researchers conducted a ...